WASHINGTON — President Trump’s Rose Garden speech on drug prices is over. The media blitz that initially animated his top health lieutenants is fading. Now the administration has to take action.

Overwhelmingly, the bulk of the Trump administration plan to bring down drug prices — to force companies to include a medication’s price in their TV commercials or expand the way pharmacy benefit managers negotiate prices for costly cancer treatments, for example — falls under the authority of Health and Human Services Department and two of its most prominent agencies, the Food and Drug Administration and the Centers for Medicare and Medicaid Services.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy